Skip to content
Biodatica
Start free

Institut Paoli-Calmettes

Marseille, Bouches-du Rhône

OncologyPhase I
Compare Sign in to watch

What changed

Study registered, no phase assigned: Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015

3mo agoTrial registeredApr 21, 2026Source filing (opens the source filing in a new tab)

Momentum

69no change

Momentum 69 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,208 pre-ticker oncology companies at Phase I

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    EARLY_PHASE1 registered

    May 29, 2020

    Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukaemia Recurrent, Mixed Phenotype Acute Leukemia · COMPLETED · sponsor: Institut Paoli-Calmettes · Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia

    ClinicalTrials.gov · NCT03957915 (opens the source filing in a new tab)

  2. Trial

    NA registered

    May 1, 2014

    Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders · COMPLETED · sponsor: Institut Paoli-Calmettes · Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015

    ClinicalTrials.gov · NCT02320656 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources